Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry
Ilaria Romani,Cristina Sarti,Patrizia Nencini,Giovanni Pracucci,Marialuisa Zedde,Vittoria Cianci,Antonia Nucera,Jessica Moller,Daniele Orsucci,Danilo Toni,Pasquale Palumbo,Carmela Casella,Vincenza Pinto,Leonardo Barbarini,Rita Bella,Umberto Scoditti,Michele Ragno,Domenico Maria Mezzapesa,Rossana Tassi,Gino Volpi,Marina Diomedi,Guido Bigliardi,Anna Maria Cavallini,Alberto Chiti,Stefano Ricci,Emanuela Cecconi,Giovanni Linoli,Simona Sacco,Maurizia Rasura,Antonello Giordano,Bruno Bonetti,Marta Melis,Lucia Princiotta Cariddi,Roberto Currò Dossi,Ilaria Grisendi,Umberto Aguglia,Maria Rita Di Ruzza,Maurizio Melis,Emilia Sbardella,Marco Vista,Raffaella Valenti,Rosa Fortunata Musolino,Bruno Passarella,Vita Direnzo,Giovanni Pennisi,Antonio Genovese,Fabio Di Marzio,Rossana Sgobio,Maurizio Acampa,Serena Nannucci,Federica Dagostino,Maria Luisa Dell'Acqua,Maria Giovanna Cuzzoni,Antonella Picchioni,Benedetta Calchetti,Francesca Notturno,Filomena Di Lisi,Stefano Forlivesi,Maria Luisa Delodovici,Susanne Christiane Buechner,Silvia Biagini,Donatella Accavone,Raffaele Manna,Amelia Morrone,Domenico Inzitari
DOI: https://doi.org/10.1016/j.jns.2024.122905
IF: 4.4
2024-02-01
Journal of the Neurological Sciences
Abstract:BACKGROUND: Fabry disease (FD) is a treatable X-linked lysosomal storage disorder caused by GLA gene variants leading to alpha-galactosidase A deficiency. FD is a rare cause of stroke, and it is still controversial whether in stroke patients FD should be searched from the beginning or at the end of the diagnostic workup (in cryptogenic strokes).METHODS: Fabry-Stroke Italian Registry is a prospective, multicentric screening involving 33 stroke units. FD was sought by measuring α-galactosidase A activity (males) and by genetic tests (males with reduced enzyme activity and females) in patients aged 18-60 years hospitalized for TIA, ischemic stroke, or intracerebral hemorrhage. We diagnosed FD in patients with 1) already known pathogenic GLA variants; 2) novel GLA variants if additional clinical, laboratory, or family-derived criteria were present.RESULTS: Out of 1906 patients, we found a GLA variant in 15 (0.79%; 95%CI 0.44-1.29) with a certain FD diagnosis in 3 (0.16%; 95%CI 0.03-0.46) patients, none of whom had hemorrhage. We identified 1 novel pathogenic GLA variant. Ischemic stroke etiologies in carriers of GLA variants were: cardioaortic embolism (33%), small artery occlusion (27%), other causes (20%), and undetermined (20%). Mild severity, recurrence, previous TIA, acroparesthesias, hearing loss, and small artery occlusion were predictors of GLA variant.CONCLUSION: In this large multicenter cohort the frequency of FD and GLA variants was consistent with previous reports. Limiting the screening for GLA variants to patients with cryptogenic stroke may miss up to 80% of diagnoses. Some easily recognizable clinical features could help select patients for FD screening.
neurosciences,clinical neurology